Tyra Biosciences, Inc. (NASDAQ:TYRA)
| Market Cap | 1.19B+46.2% |
| Revenue (ttm) | 0 |
| Net Income | -148.56M-40.4% |
| EPS | -2.40-34.8% |
| Shares Out | 59.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,268.288 |
| Open | 20.12 |
| Previous Close | 20.39 |
| Day's Range | 19.61 - 20.12 |
| 52-Week Range | 13.29 - 40.65 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 45.17(+126.66%) |
| Earnings Date | Nov 4, 2026 |
Tyra Biosciences, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About TYRA
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TYRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TYRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TYRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TYRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TYRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TYRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TYRA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $28.42M |
| XBIState Street SPDR S&P Biotech ETF | $24.48M |
| IWMiShares Russell 2000 ETF | $19.79M |
| VXFVanguard Extended Market ETF | $8.63M |
| IBBiShares Biotechnology ETF | $8.14M |
| IWOiShares Russell 2000 Growth ETF | $6.99M |
Estimated from each fund’s disclosed top holdings × AUM
TYRA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TYRA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score